Galera Therapeutics has dosed the first patient in a Phase I/II clinical trial of GC4419 for the treatment of locally advanced pancreatic cancer (LAPC).

Dosing was conducted at The University of Texas MD Anderson Cancer Centre in Houston, Texas, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The adaptive, dose escalation trial is aimed at evaluating the safety and anti-tumour effect of GC4419 in combination with stereotactic body radiation therapy (SBRT), compared with SBRT alone, in LAPC patients.

A total of 48 patients will be included in the trial, which will also evaluate safety and tolerability to establish the maximum tolerated dose of SBRT when combined with GC4419 or placebo.

Galera Therapeutics president and CEO Mel Sorensen said: “Our recently completed 223-patient Phase IIb trial of GC4419 in head and neck cancer demonstrated GC4419’s ability to limit radiation-induced healthy tissue damage by reducing the duration, incidence and severity of radiation and chemotherapy-induced oral mucositis.

“The trial demonstrated GC4419’s ability to limit radiation-induced healthy tissue damage by reducing the duration, incidence and severity of radiation and chemotherapy-induced oral mucositis.”

“We seek to build upon these results with this anti-tumour trial in LAPC and generate robust data to demonstrate GC4419’s potential to change the management of radiation therapy by both protecting normal tissue and improving the effectiveness of radiation, making more surgical resections possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, preclinical data have showed GC4419’s potential to enhance the effectiveness of radiation on cancer cells while preventing toxicity in normal tissue.

GC4419 leverages Galera’s dismutase mimetic platform to rapidly turn the superoxide produced by radiation therapy into hydrogen peroxide, which is fatal to cancer cells in high concentrations.

The drug previously received breakthrough therapy designation from the US Food and Drug Administration (FDA) for reducing the duration, incidence, and severity of severe oral mucositis (SOM) induced by radiation therapy with or without systemic therapy.